Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy

Lymphoma
16/07/2020

Br J Haematol. 2020 Jul 15. doi: 10.1111/bjh.16951. Online ahead of print.

NO ABSTRACT